You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

187 search results for: symposium

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.
View more
Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Dermatology
The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?

Dermatology
Presentations from the ADVENT symposium at the EAACI 2023 congress on targeting type 2 Inflammation in children with atopic dermatitis.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Dermatology
Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.
View more
EAACI 2023 | What is New in the Treatment of Children
expert video

EAACI 2023 | What is New in the Treatment of Children

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more
New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children

Dermatology
Highlights from the ADVENT WCD 2023 symposium delving into the pathophysiology and management of atopic dermatitis in children.
View more
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

Dermatology
This video from the March 2024 ADVENT AD symposium features the final panel discussion and conclusion. Dr. Eric Simpson, Dr. Katrina Abuabara, and Dr. Lawrence Eichenfield discuss topics related to early intervention in AD and the impact of the cumulative disease burden that may manifest as atopic or nonatopic, systemic comorbidities. The faculty also fields several questions submitted by the audience. Dr. Simpson concludes the panel discussion with a brief overview of the symposium.
View more
Long-term Impacts of AD and the Potential Benefit of Early Intervention
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.
View more
The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

Dermatology
Dr. Lisa Beck highlights the association between epidermal barrier dysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.
View more
Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Katrina Abuabara discusses the concept of inflamm-aging in older adult patients. She explains how the term is defined through measures of systemic inflammatory markers and how immunosenescence can contribute to systemic comorbidities in older adults with AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region